Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio

LELYSTAD and 'S-HERTOGENBOSCH, The Netherlands, April 28, 2010 /PRNewswire/ -- Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.